Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma

New England Journal of Medicine

Volumn 359, Issue 9, 2008, Pages 906-917

  San Miguel, Jesús F ^a,s   Schlag, Rudolf ^b   Khuageva, Nuriet K ^c   Dimopoulos, Meletios A ^d   Shpilberg, Ofer ^e   Kropff, Martin ^f   Spicka, Ivan ^g   Petrucci, Maria T ^h   Palumbo, Antonio ⁱ   Samoilova, Olga S ^j   Dmoszynska, Anna ^k   Abdulkadyrov, Kudrat M ^l   Schots, Rik ^m   Jiang, Bin ⁿ   Mateos, Maria Victoria ^a   Anderson, Kenneth C ^o   Esseltine, Dixie L ^p   Liu, Kevin ^q   Cakana, Andrew ^r   Van De Velde, Helgi ^r   Richardson, Paul G ^o   more..

^a Centro de Investigacion del Cancer   (Spain)

^b Praxisklinik Dr Schlag   (Germany)

^c SP Botkin Moscow City Clinical Hospital   (Russian Federation)

^d UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^e RABIN MEDICAL CENTER   (Israel)

^f UNIVERSITY OF MÜNSTER   (Germany)

^g CHARLES UNIVERSITY   (Czech Republic)

^h SAPIENZA UNIVERSITY OF ROME   (Italy)

ⁱ UNIVERSITY OF TURIN   (Italy)

^j LOBACHEVSKY STATE UNIVERSITY OF NIZHNY NOVGOROD   (Russian Federation)

^k MEDICAL UNIVERSITY OF LUBLIN   (Poland)

^l State Research Institute of Hematology and Transfusiology   (Russian Federation)

^m Belgian Hematological Society   (Japan)

ⁿ PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

^o DANA FARBER CANCER INSTITUTE   (United States)

^p MILLENNIUM PHARMACEUTICALS INC   (United States)

^q JOHNSON AND JOHNSON   (United States)

^r Hospital Universitario de Salamanca ^*

^s HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 MICROGLOBULIN; BORTEZOMIB; MELPHALAN; PREDNISONE;

AGED; ANEMIA; ANOREXIA; ARTHRALGIA; ARTICLE; ASTHENIA; BACKACHE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DEEP VEIN THROMBOSIS; DIARRHEA; DISEASE COURSE; DIZZINESS; DRUG EFFICACY; DRUG MEGADOSE; DYSPNEA; FATIGUE; FEMALE; FEVER; GASTROINTESTINAL SYMPTOM; HEMATOLOGIC DISEASE; HERPES ZOSTER; HUMAN; HYPOKALEMIA; INFECTION; INSOMNIA; LEUKOPENIA; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; NAUSEA; NEURALGIA; NEUROLOGIC DISEASE; NEUTROPENIA; PERIPHERAL EDEMA; PERIPHERAL NEUROPATHY; PHASE 3 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; SURVIVAL; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING;

EID: 50449086728     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa0801479     Document Type: Article

References (35)

1. Alexanian R, Haut A, Khan AU, et al. Treatment for multiple myeloma: combination chemotherapy with different melphalan dose regimens. JAMA 1969;208:1680-5.
2. Kyle RA, Rajkumar SV. Multiple myeloma. N Engl J Med 2004;351:1860-73. [Erratum, N Engl J Med 2005;352:1163.]
3. Boccadoro M, Marmont F, Tribalto M, et al. Multiple myeloma: VMCP/VBAP alternating combination chemotherapy is not superior to melphalan and prednisone even in high-risk patients. J Clin Oncol 1991;9:444-8.
4. Facon T, Mary JY, Pégourie B, et al. Dexamethasone-based regimens versus melphalan-prednisone for elderly multiple myeloma patients ineligible for high-dose therapy. Blood 2006;107:1292-8.
5. Myeloma Trialists' Collaborative Group. Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials. J Clin Oncol 1998;16:3832-42.
6. Hernández JM, Garcia-Sanz R, Golvano E, et al. Randomized comparison of dexamethasone combined with melphalan versus melphalan with prednisone in the treatment of elderly patients with multiple myeloma. Br J Haematol 2004;127:159-64.
7. Attal M, Harousseau JL, Stoppa AM, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Engl J Med 1996;335:91-7.
8. Barlogie B, Jagannath S, Vesole DH, et al. Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma. Blood 1997;89:789-93.
9. Child JA, Morgan GJ, Davies FE, et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003;348:1875-83.
10. Ries LAG, Eisner MP, Kosary CL, et al. SEER cancer statistics review, 1975-2002. Bethesda, MD: National Cancer Institute, 2005.
11. Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003;348:2609-17.
12. Richardson PG, Sonneveld P, Schuster M, et al. Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. Blood 2007;110:3557-60.
13. Richardson PG, Sonneveld P, Schuster MW, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005;352:2487-98.
14. Mitsiades N, Mitsiades CS, Richardson PG, et al. The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood 2003;101:2377-80.
15. Ma MH, Yang HH, Parker K, et al. The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents. Clin Cancer Res 2003;9:1136-44.
16. Berenson JR, Yang HH, Sadler K, et al. Phase I/II trial assessing bortezomib and melphalan combination therapy for the treatment of patients with relapsed or refractory multiple myeloma. J Clin Oncol 2006;24:937-44.
17. Mateos MV, Hernández JM, Hernández MT, et al. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study. Blood 2006;108:2165-72.
18. Mateos MV, Hernández JM, Hernández MT, et al. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: updated time-to-events results and prognostic factors for time to progression. Haematologica 2008;93:560-5.
19. Richardson PG, Briemberg H, Jagannath S, et al. Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol 2006;24:3113-20.
20. Kyle RA, Yee GC, Somerfield MR, et al. American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma. J Clin Oncol 2007;25:2464-72.
21. Bladé J, Samson D, Reece D, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Br J Haematol 1998;102:1115-23.
22. Durie BG, Harousseau JL, Miguel JS, et al. International uniform response criteria for multiple myeloma. Leukemia 2006;20:1467-73. [Errata, Leukemia 2006;20:2220, 2007;21:1134.]
23. O'Brien PC, Fleming TR. A multiple testing procedure for clinical trials. Biometrics 1979;35:549-56.
24. Greipp PR, San Miguel J, Durie BG, et al. International staging system for multiple myeloma. J Clin Oncol 2005;23:3412-20. [Erratum, J Clin Oncol 2005;23:6281.]
25. Facon T, Mary JY, Hulin C, et al. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial. Lancet 2007;370:1209-18.
26. Palumbo A, Bringhen S, Caravita T, et al. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet 2006;367:825-31.
27. Hulin C, Facon T, Rodon P, et al. Melphalan-prednisone-thalidomide (MP-T) demonstrates a significant survival advantage in elderly patients 75 years with multiple myeloma compared with melphalan-prednisone (MP) in a randomized, double-blind, placebo-controlled trial, IFM 01/01. Blood 2007;110:11a. abstract.
28. Palumbo A, Falco P, Corradini P, et al. Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA-Italian Multiple Myeloma Network. J Clin Oncol 2007;25:4459-65.
29. Richardson PG, Niesvizky R, Anderson KC, Bladé J. Re: When you look matters: the effect of assessment schedule on progression-free survival. J Natl Cancer Inst 2008;100:373.
30. Panageas KS, Ben-Porat L, Dickler MN, Chapman PB, Schrag D. When you look matters: the effect of assessment schedule on progression-free survival. J Natl Cancer Inst 2007;99:428-32.
31. Jagannath S, Barlogie B, Berenson J, et al. A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol 2004;127:165-72.
32. Anagnostopoulos A, Gika D, Symeonidis A, et al. Multiple myeloma in elderly patients: prognostic factors and outcome. Eur J Haematol 2005;75:370-5.
33. Augustson BM, Begum G, Dunn JA, et al. Early mortality after diagnosis of multiple myeloma: analysis of patients entered onto the United Kingdom Medical Research Council trials between 1980 and 2002 - Medical Research Council Adult Leukaemia Working Party. J Clin Oncol 2005;23:9219-26.
34. San Miguel JF, Richardson P, Sonneveld P, et al. Frequency, characteristics, and reversibility of peripheral neuropathy (PN) in the APEX trial. Blood 2005;106:111a. abstract.
35. Anderson KC, Kyle RA, Rajkumar SV, Stewart AK, Weber D, Richardson P. Clinically relevant end points and new drug approvals for myeloma. Leukemia 2008;22:231-9.